Datos del Documento


Por favor, use este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/1506
Registro de Metadatos Completo
Campo Dublin Core Valor Idioma
dc.contributor.authorLlorente, José L.-
dc.contributor.authorMartín Oviedo, Carlos-
dc.contributor.authorVivanco, Blanca-
dc.contributor.authorÁlvarez Marcos, César-
dc.contributor.authorGarcía-Inclán, Cristina-
dc.contributor.authorScola, Bartolomé-
dc.contributor.authorHermsen, Mario A.-
dc.date.accessioned2011-12-15T12:00:00Z-
dc.date.available2011-12-15T12:00:00Z-
dc.date.issued2011-
dc.identifier.urihttps://ria.asturias.es/RIA/handle/123456789/1506-
dc.description.abstractBackground: Sinonasal squamous cell carcinomas (SNSCC) are rare tumors with no etiological link to tobacco and alcohol, as opposed to other squamous cell carcinomas of the head and neck. Despite improvements in the field of surgery and radiotherapy, patients with these tumors still face a very unfavorable prognosis, partly due to its localization in a complex anatomical area, which is of special relevance for surgery and postoperative treatment. Therefore, there is a need for new therapeutic possibilities for this tumor type. Methods: Gene copy numbers of epidermal growth factor receptor (EGFR) and erythroblastic leukemia viral oncogene homolog 2 (ERBB2) were analyzed by FISH and MLPA and protein expression was evaluated by immunohistochemistry in 54 specimens SNSCC and the results were correlated with clinico-pathological and follow-up data. Results: EGFR gene copy number increase were observed in 20/45 (44%) cases, and 21/54 (39%) tumors showed EGFR protein overexpression. Eight of 38 tumors (21%) showed ERBB2 copy number increase, and 4/54 (7%) exhibited elevated protein expression levels. Both copy number increase and protein overexpression of EGFR and ERBB2 were mutually exclusive. KRAS mutations were absent in 37 cases analyzed. Conclusion: A substancial proportion of SNSCC carry alterations in EGFR or ERBB2. Together with the absence of KRAS mutations, these findings indicate that therapies targeting these molecules could be a promising addition to the therapeutical options for these tumors.eng
dc.description.sponsorshipThis work was supported by grants PI05-1387, PI08-1599 and EMER07-048 of Fondos de Investigación Sanitaria (FIS) and RD06/0020/0034 of Red Temática de Investigación Cooperativa en Cáncer (RTICC), Spain.eng
dc.language.isoengeng
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/deed.eseng
dc.subjectMaxillary sinuseng
dc.subjectEthmoid sinuseng
dc.subjectSinonasaleng
dc.subjectSquamous cell carcinomaeng
dc.subjectEGFReng
dc.subjectERBB2eng
dc.subjectKRASeng
dc.subjectTherapyeng
dc.titleGene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinomaeng
dc.typepreprinteng
Aparece en las colecciones: Open Access DRIVERset
Sanidad

Archivos en este documento:
Fichero Tamaño Formato  
Archivo.pdf104.37 kBAdobe PDFVer/Abrir
Mostrar el registro Básico


Ver estadísticas del documento


Este documento está sujeto a una licencia Creative Commons: Licencia Creative Commons Creative Commons